SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Achieves Major Milestone with FDA Submission for its Groundbreaking 12-Lead ECG Synthesis Software.
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference.
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology.
HeartBeam, Inc. (NASDAQ:BEAT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Rob Eno - Chief Executive Officer Branislav Vajdic - President and Founder Tim Cruickshank - Chief Financial Officer Conference Call Participants Operator Greetings, and welcome to the HeartBeam Third Quarter 2024 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Appoints Robert Eno as Chief Executive Officer in Preparation for US Commercialization.
- Data continue to support revumenib's potential to enhance current standard of care agents - - 96% CRc (23 of 24 pts) observed in BEAT AML trial exploring revumenib in combination with venetoclax/azacitidine in newly diagnosed mNPM1 or KMT2Ar AML - - 52% CRc (14 of 27 pts) observed in AUGMENT-102 trial of revumenib in combination with fludarabine-cytarabine in acute leukemia patients with R/R mNPM1, NUP98r or KMT2Ar - WALTHAM, Mass. , June 14, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated data from multiple combination trials of revumenib, the Company's potent, selective, small molecule menin inhibitor, in patients with acute leukemias.
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam's Artificial Intelligence Algorithm Combined with Vectorcardiography (VCG) Outperforms Expert Cardiologists in Detecting Arrhythmias.
HeartBeam, Inc. (NASDAQ: BEAT) Q1 2024 Earnings Conference Call on May 9, 2024 at 4:30 PM ET with Company Participants Branislav Vajdic, Rob Eno, Rick Brounstein, and Brooks Hamilton, as well as Conference Call Participants Leo Carpio. Thank you for joining us for the HeartBeam First Quarter 2024 Financial Results Conference Call.
HeartBeam showcases successful outcomes in utilizing its artificial intelligence technology to identify irregular heart rhythms.
HeartBeam (NASDAQ: BEAT ) just reported results for the fourth quarter of 2023. HeartBeam reported earnings per share of -13 cents.